Gilde Healthcare closes €416m fund targeting remote monitoring businesses

The fund will invest in venture and growth stage companies developing services such as remote monitoring and home care of patients, which Gilde Healthcare managing partner Pieter van der Meer (pictured) said was “now more relevant than ever in the fight against COVID-19."


The new fund, which Gilde Healthcare said was oversubscribed, targets growth opportunities in a broad range of healthcare sectors including digital health, medtech and therapeutics both in Europe and North America.

“The fund will have a special attention for private healthcare companies enabling improved care at affordable cost,” a Gilde Healthcare statement said.

The Gilde Healthcare V fund will typically make equity investments in a single portfolio company of between €10-40 million.

Gilde Healthcare V was raised in a single close and is backed by a mix of international investors including banks, pension funds, fund-of-funds, sovereign funds, endowments, family offices, entrepreneurs and other Gilde partners. Disclosed investors include Royal Philips and Rabo Corporate Investments from The Netherlands, HANIEL and KfW Capital from Germany, BNP Paribas Fortis Private Equity and Belgian Growth Fund from Belgium, Danish Growth Fund from Denmark and the European Investment Fund (EIF) from Luxembourg. 

Van der Meer said: "The healthcare landscape in Europe and the US is changing rapidly, driven by the need for more patient centric care and more focus on value based care. With our new fund we will continue our strategy to invest in venture and growth stage companies developing novel solutions that enable better healthcare outcomes at reduced costs.”

Recent Gilde Healthcare exits include the sale of infectious disease (including COVID-19) diagnostic platform STAT-Dx to Qiagen, the trade sale of Breath Therapeutics (treatment of lung transplant rejection) to Zambon Pharma and the NASDAQ listing of Axonics, focused on the treatment of overactive bladder.

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity.